ÍøºìºÚÁÏ

Skip to main content
(352) 265-7337

Michael J Haller, MD : Research

Pediatric Endocrinologist (Child Hormone Specialist)

Photo of Michael J Haller
(352) 265-7337 MyUFÍøºìºÚÁÏ

Research at a glance

Top areas of exploration

  • Diabetes Mellitus, Type 1 , 65 publications
  • Insulin , 15 publications
  • Blood Glucose , 14 publications
  • Glycated Hemoglobin , 13 publications

Research activity

145 publications

3,743 citations

Why is this important?

Focus

Dr. Haller's research focuses on predicting, preventing, and ultimately reversing type 1 diabetes through his participation in numerous clinical trials utilizing immunotherapies. Dr. Haller serves as the Principal Investigator for the University of Florida TrialNet Clinical Center, Chair of the TEDDY Clinical Implementation Committee, and PI of the UF/Stanford ECHO Collaborative. Dr. Haller also leads and participates in technology studies seeking to improve the lives of people living with diabetes through the use of pumps, continuous glucose monitors, and systems that automate insulin delivery.

Active clinical trials

PROTECT Extension Study

The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in participants who completed the PROTECT study.

Investigator
Michael J Haller
Status
Accepting Candidates
Ages
9 Years - 19 Years
Sexes
All

My publications

145 publications

2025

An Exploratory Cost-Effectiveness Analysis of Immune Therapy in Delaying the Initiation of Automated Insulin Delivery Systems in Type 1 Diabetes

Diabetes Technology & Therapeutics

2025

Considerations for more actionable consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Reply to Mallone R [letter]

Diabetologia

2025

Developing an automated algorithm for identification of children and adolescents with diabetes using electronic health records from the OneFlorida+ clinical research network.

Diabetes, obesity & metabolism

•

2025

Emerging Immunotherapies for Disease Modification of Type 1 Diabetes.

Drugs

•

2025

Looking back at the TEDDY study: lessons and future directions

Nature Reviews Endocrinology